A 3-day intensive program for biotech & pharma professionals, cell therapy researchers, and clinical genomics practitioners. Immune repertoire (TCR/BCR) sequencing analysis and CRISPR-Cas9 engineering for immunotherapy applications.
Proven track record since 2018
Now restarting under OmixLab with a specialised CRISPR-Cas9 & immunome focus
Two tiers — individual and corporate. All tiers include 3 days of training, meals, course materials, and a certificate. Invoice issued.
Date and venue to be announced. Register interest now to receive priority notification and early-bird pricing.
The Dubai program has real attendance history — not aspirational projections. Real people paid real money to attend from four countries, before COVID interrupted it in 2020. OmixLab is restarting it with a sharpened focus on immunome analysis and CRISPR-Cas9 T-cell engineering for the Gulf's booming cell therapy sector.
28 paying participants from UAE, Saudi Arabia, Egypt, and Algeria. NGS Data Analysis & CRISPR-Cas9. Sold out.
15 participants. Regional attendees across the Gulf and North Africa. COVID disrupted the 2020 edition before it could run.
Now under OmixLab. Specialised immunome analysis and CRISPR-Cas9 T-cell engineering — aligned to Gulf biotech investment in cell and gene therapy.
TCR/BCR sequencing, V(D)J recombination, library prep principles, QC and preprocessing of immune repertoire data.
Clonotype detection, repertoire diversity, clonal expansion metrics, visualisation of immune repertoire landscapes.
Mechanism of CRISPR-Cas9, guide RNA design tools (Benchling, CRISPOR), off-target prediction, efficiency scoring.
CAR-T cell design principles, integration site analysis, safety considerations, computational validation of constructs.
Published immunotherapy dataset walkthroughs, troubleshooting session, bring your own data — run your own pipeline.
PhD students and postdocs working on immunology, oncology, or infectious disease research who need computational tools to process immune sequencing data.
Clinicians and clinical scientists at hospitals or diagnostics labs expanding into immune profiling or cell therapy clinical applications.
Scientists in biotech or pharmaceutical companies working on cell and gene therapy, CAR-T programmes, or immunotherapy pipelines.
Date and venue are TBC. Register your interest now and you'll be first to receive: the confirmed date, early-bird pricing access, and a detailed programme PDF.
No payment required now. We'll confirm details and early-bird pricing within 48 hours.